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Summary
 
Merozoite surface protein–1 (MSP-1) of the human malaria parasite 
 
Plasmodium falciparum
 
 un-
dergoes at least two endoproteolytic cleavage events during merozoite maturation and release,
and erythrocyte invasion. We have previously demonstrated that mAbs which inhibit erythro-
cyte invasion and are specific for epitopes within a membrane-proximal, COOH-terminal do-
main of MSP-1 (MSP-1
 
19
 
) prevent the critical secondary processing step which occurs on the
surface of the extracellular merozoite at around the time of erythrocyte invasion. Certain other
anti–MSP-1
 
19
 
 mAbs, which themselves inhibit neither erythrocyte invasion nor MSP-1 sec-
ondary processing, block the processing-inhibitory activity of the first group of antibodies and
are termed blocking antibodies. We have now directly quantitated antibody-mediated inhibi-
tion of MSP-1 secondary processing and invasion, and the effects on this of blocking antibod-
ies. We show that blocking antibodies function by competing with the binding of processing-
inhibitory antibodies to their epitopes on the merozoite. Polyclonal rabbit antibodies specific
for certain MSP-1 sequences outside of MSP-1
 
19
 
 also act as blocking antibodies. Most signifi-
cantly, affinity-purified, naturally acquired human antibodies specific for epitopes within the
NH
 
2
 
-terminal 83-kD domain of MSP-1 very effectively block the processing-inhibitory activ-
ity of the anti-MSP-1
 
19
 
 mAb 12.8. The presence of these blocking antibodies also completely
abrogates the inhibitory effect of mAb 12.8 on erythrocyte invasion by the parasite in vitro.
Blocking antibodies therefore (
 
a
 
) are part of the human response to malarial infection; (
 
b
 
) can
be induced by MSP-1 structures unrelated to the MSP-1
 
19
 
 target of processing-inhibitory anti-
bodies; and (
 
c
 
) have the potential to abolish protection mediated by anti–MSP-1
 
19
 
 antibodies.
Our results suggest that an effective MSP-1
 
19
 
–based falciparum malaria vaccine should aim to
induce an antibody response that prevents MSP-1 processing on the merozoite surface.
 
T
 
he development of an effective malaria vaccine has be-
come a major public health challenge. The protozoan
organisms responsible for the disease, members of the genus
 
Plasmodium
 
, have a complicated life cycle, and in the hu-
man host the parasite exists in at least four morphologically
and antigenically distinct forms. As a result, in individuals
exposed to malarial infection, the immune response against
the parasite is complex, and several stages of the life cycle
are being explored as potential targets for vaccine-mediated
immune intervention. Acute clinical malaria, which is of-
ten life-threatening in the case of infection with 
 
Plasmodium
falciparum
 
, is associated with replication of the asexual blood-
stage parasite in circulating erythrocytes. Human passive
immunization studies using antibodies isolated from donors
clinically immune to falciparum malaria have indicated that
antimalarial IgG can prevent this replication (1–4), and sur-
face components of the infected erythrocyte and invasive
merozoite stage of the parasite have therefore been studied
intensively for their ability to induce protective immune
responses. The merozoite expresses a number of surface
proteins, one or more of which are thought to mediate the
initial interaction between parasite and host erythrocyte (5,
6). Recent work in this laboratory has focused on the pro-
teolytic processing of merozoite surface protein–1 (MSP-1).
 
1
 
Initially synthesized as a large (
 
z
 
200 kD) precursor during
intracellular merozoite development, MSP-1 is present on
the surface of the released merozoite in the form of a mul-
ticomponent protein complex derived via proteolytic pro-
 
1
 
Abbreviations used in this paper:
 
 EGF, epidermal growth factor; HRP,
horseradish peroxidase–conjugated; MSP-1, merozoite surface protein–1;
T, Tween 20; TLCK, tosyl-
 
l
 
-lysyl choromethyl ketone.
  
1690
 
Blocking Antibodies in Malaria
 
cessing (7, 8). At some point between merozoite release
and completion of erythrocyte invasion, the membrane-
bound component (MSP-1
 
42
 
) of this surface complex is fur-
ther cleaved at a single site to form two fragments, MSP-1
 
33
 
and MSP-1
 
19
 
. This results in the majority of the complex
being shed from the parasite surface, leaving only MSP-1
 
19
 
,
which represents the extreme COOH-terminal end of the
MSP-1 precursor and is comprised of two epidermal growth
factor (EGF)-like motifs, to be taken into the invaded cell
on the parasite surface (9–12). Significantly, this so-called
secondary processing of MSP-1 is conserved across the ge-
nus (13–15) and invariably goes to completion when a
merozoite successfully invades a red blood cell, suggesting
that it is a necessary step in the invasion pathway.
Studies in the rodent 
 
Plasmodium chabaudi
 
 and 
 
Plasmo-
dium yoelii
 
 malaria models have shown that passive immu-
nization with certain anti–MSP-1
 
19
 
 mAbs, or immuniza-
tion with recombinant MSP-1
 
19
 
, can afford an astonishing
degree of protection against a blood-stage challenge infec-
tion (16–20). Consistent with this, a number of reports
have shown that polyclonal antibodies (21, 22) or mAbs (9,
23, 24) specific for epitopes within the 
 
P. falciparum
 
 MSP-1
 
19
 
domain can prevent erythrocyte invasion by merozoites in
vitro. To investigate the mechanisms involved in this inva-
sion inhibition, we recently studied a panel of anti–MSP-1
 
19
 
mAbs, and found that those antibodies which most effec-
tively prevent invasion can, upon binding to MSP-1 on the
surface of intact 
 
P. falciparum
 
 merozoites, completely pre-
vent secondary processing of the molecule. Furthermore,
of those mAbs which do not affect the processing, some
can interfere with the processing-inhibitory activity of the
first group of antibodies (25). This second group of anti-
bodies was referred to as blocking antibodies.
In this study we extend this work to show that blocking
antibodies act by competing with processing-inhibitory
mAbs for binding to the merozoite surface. We show that
polyclonal antibodies raised against MSP-1 sequences out-
side of MSP-1
 
19
 
 can also have blocking properties similar to
those of the anti–MSP-1
 
19
 
 mAbs previously identified. Of
most significance, human antibodies specific to the NH
 
2
 
-
terminal domain of MSP-1, affinity-purified from sera of
individuals naturally exposed to falciparum malaria, are po-
tent blocking antibodies which can completely abolish the
activity of invasion-inhibitory antibodies in vitro. Our ob-
servations reveal a mechanism by which the parasite can
avoid the action of a class of protective antibodies, and have
important implications for the optimal design, evaluation,
and administration of MSP-1–based malaria vaccines.
 
Materials and Methods
 
Polyclonal and Monoclonal Antibodies.
 
Murine anti–MSP-1
 
19
 
 mAbs
2.2, 7.5, 12.8, 12.10, 111.4, 117.2, 1E1, 2F10, 7E5, 8A12, and
12D11; the anti–MSP-1
 
83
 
 mAb 89.1 and the mAb 25.1, which is
specific for 
 
P. yoelii
 
 MSP-1; and the human anti–MSP-1
 
33
 
 mAb
X509 have all been previously described (7, 9, 10, 25–27). All
mAbs were purified by affinity chromatography on protein A– or
protein G–Sepharose (Pharmacia Biotech, St. Albans, Hertford-
shire, UK) before use (28). A panel of polyclonal anti–MSP-1 an-
tisera was raised in rabbits against defined regions of MSP-1 ex-
pressed as fusion proteins in 
 
Escherichia coli
 
 (8); IgG was purified
from these sera by ion exchange chromatography on DEAE Sepha-
dex (Pharmacia Biotech) using standard methods (28). The poly-
clonal rabbit antiserum reactive with the MSP-1
 
33
 
 fragment of the
Wellcome MSP-1 (Rb anti–MSP-1
 
33
 
) was raised against a recom-
binant protein expressing a 93–amino acid region from within the
NH
 
2
 
-terminal half of MSP-1
 
42
 
; therefore, the antibodies recog-
nize both MSP-1
 
42
 
 and MSP-1
 
33
 
, and show absolutely no reactiv-
ity with MSP-1
 
19
 
 (13). Pooled human serum obtained from adult
Gambian donors clinically immune to falciparum malaria was a kind
gift of Dr. Hilton Whittle (Medical Research Council Laboratories,
Fajara, The Gambia, West Africa). Human serum from European
donors who had never been exposed to malaria (nonimmune
sera) was obtained from the Blood Transfusion Centre (Colin-
dale, UK) and pooled.
 
Preparation of Recombinant Antigens.
 
Production of a recombi-
nant pGEX-3X plasmid (29) to express the MSP-1
 
19
 
 domain of
the 
 
P. falciparum
 
 (Wellcome strain) MSP-1 fused to 
 
Schistosoma
japonicum
 
 glutathione S-transferase has been described previously
(26). Fusion protein was adsorbed to glutathione agarose (Sigma
Chemical Co., St. Louis, MO), and the malarial portion (rMSP-
1
 
19
 
) cleaved in situ from the carrier protein (30) by overnight in-
cubation with Factor Xa (Boehringer Mannheim, Mannheim,
Germany) at 4
 
8
 
C. Eluted protein was further purified by gel fil-
tration in PBS on Sephadex G50 Superfine (Pharmacia Biotech),
and concentrated by ultrafiltration using a YM1 membrane (Am-
icon, Ltd., Stonehouse, Gloucs., UK).
Recombinant expression plasmid pME6 encodes Leu
 
208
 
 to
Asp
 
416
 
 of the 
 
P. falciparum
 
 Wellcome strain MSP-1 gene (number-
ing according to reference 31), as an NH
 
2
 
-terminal fusion with
 
b
 
-galactosidase (8). Fusion protein (also referred to as pME6; ref-
erence 8) was purified by affinity chromatography on 
 
p
 
-ami-
nophenyl-
 
b
 
-
 
d
 
-thiogalactopyranoside-agarose (32) and stored as a
precipitate in 50% (wt/vol) ammonium sulfate.
 
Radioiodination of Antibodies.
 
Protein G–purified mAbs 12.8,
12.10, and X509, and purified rabbit anti-IgG antibodies (Sera-
Lab, Ltd., Sussex, UK) were labeled at 4
 
8
 
C with 
 
125
 
I by the Iodogen
(Pierce Chemical Co., Rockford, IL) method (33). Labeled anti-
body was separated from free isotope by gel filtration on a PD-10
column (Pharmacia Biotech) preequilibrated with PBS contain-
ing 1% BSA and 0.02% (wt/vol) sodium azide. The specific activ-
ity of the labeled antibody was 
 
z
 
3.1 
 
3
 
 10
 
6
 
 cpm 
 
m
 
g
 
2
 
1
 
. Labeled
antibody was stored at 4
 
8
 
C.
 
Culture and Biosynthetic Radiolabeling of P. falciparum, and Mero-
zoite Purification.
 
Highly synchronous blood-stage cultures of
the FCB-1 and T9/96 isolates of 
 
P. falciparum
 
 were maintained in
vitro in human A
 
1
 
 erythrocytes, and the naturally released mero-
zoites were purified by filtration through 3 
 
m
 
m and 1.2 
 
m
 
m pore-
size acrylic membrane filters as previously described (34). Mero-
zoites were recovered from the filtrate by centrifugation and
washed twice in ice-cold PBS, supplemented with the protease
inhibitors leupeptin, antipain, and aprotinin, all at 10 
 
m
 
g ml
 
2
 
1
 
 and
tosyl-
 
l
 
-lysyl choromethyl ketone (TLCK) at 10 
 
m
 
M. Merozoites
not immediately used were pelleted by centrifugation and stored
in aliquots at 
 
2
 
70
 
8
 
C. Merozoite preparations were consistently
free of schizont contamination, as determined by microscopic
analysis of Giemsa-stained samples.
When required, schizont-enriched cultures were metabolically
radiolabeled with [
 
35
 
S]methionine and cysteine (Pro-mix
 
TM
 
; Am-
ersham International, Little Chalfont, UK), placed back into cul-
ture in medium containing 0.5% (wt/vol) Albumax
 
TM
 
 (GIBCO 
1691
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BRL, Paisley, UK), and allowed to undergo merozoite release in
the presence of fresh erythrocytes as previously described (10).
Labeled MSP-1
 
33
 
 was immunoprecipitated from harvested culture
medium using mAb X509 coupled to Sepharose, and analyzed by
SDS-PAGE and fluorography as previously described (10, 11).
When appropriate, ring-stage parasitemia in cultures after reinva-
sion was assessed by microscopic examination of Giemsa-stained
thin blood films.
 
Quantitation of Antibody-mediated Inhibition of MSP-1 Secondary
Processing.
 
Analysis and quantitation of secondary processing of
MSP-1 in merozoite preparations was by modification of an assay
described previously (13, 34). Washed merozoites were resus-
pended in ice-cold 50 mM Tris-HCl, pH 7.5, containing 10 mM
CaCl
 
2
 
 and 2 mM MgCl
 
2
 
, supplemented with the following pro-
tease inhibitors: antipain, leupeptin, aprotinin, and TLCK (reac-
tion buffer). Aliquots of 
 
z
 
10
 
9
 
 merozoites were dispensed into
1.4-ml Eppendorf tubes on ice, and the parasites were pelleted in
a microfuge at 12,000 
 
g
 
 for 2 min at 4
 
8
 
C. The buffer was aspi-
rated, and individual merozoite pellets were resuspended on ice
in 20 
 
m
 
l of reaction buffer further supplemented with protease in-
hibitors or antibodies as appropriate. Merozoites were maintained
on ice for 15 min to allow antibody binding, then transferred to a
37
 
8
 
C water bath for 1 h to allow processing to proceed. Assays al-
ways included the following controls: a “positive processing” con-
trol sample of merozoites, resuspended in reaction buffer only; a
negative “no processing” sample of merozoites, resuspended in
reaction buffer plus 1 mM PMSF; and a zero time (0 h) control,
in which processing was immediately stopped before the 37
 
8
 
C in-
cubation step by the addition of an equal volume of 2% (vol/vol)
NP-40 (BDH Chemicals, Ltd., Poole, UK; reference 13).
Processing was stopped by the addition of 20 
 
m
 
l of 2% NP-40.
Samples were vortexed and extracted on ice for 1 h, then centri-
fuged for 15 min at 12,000 
 
g.
 
 The supernatant was removed to a
new tube containing an equal volume of 2 
 
3
 
 SDS-PAGE sample
buffer, and 5–20 
 
m
 
l of each sample was subjected to electrophoresis
under nonreducing conditions on 12.5 or 15% polyacrylamide
minigels (Pharmacia Biotech) before being transferred electro-
phoretically to nitrocellulose (Schleicher and Schuell, Inc., Das-
sel, Germany, 0.2 
 
m
 
m pore size). Blots were blocked in PBS con-
taining 7% (wt/vol) BSA and probed with a 1:100 dilution of Rb
anti–MSP-1
 
33
 
. After washing three times in PBS containing 0.05%
(vol/vol) Tween -20 (PBS/T), bound antibody was detected by
further incubation with radioiodinated anti–rabbit IgG. Blots
were washed for 1 h with several changes of PBS/T, and then
dried. Bands on the blot corresponding to MSP-1
 
33
 
 and MSP-1
 
42
 
were visualized by autoradiography; direct quantitation of the ra-
dioactivity associated with these bands was then performed by ex-
cising the appropriate regions from the blots and measuring the
associated radioactivity (in cpm) in a gamma counter. Merozoite
samples were routinely assayed in triplicate, and results were ex-
pressed as mean percentage MSP-1
 
42
 
 processing, using the for-
mula [(
 
X
 
 
 
2
 
 
 
B
 
)/(A 2 B) 3 100], where A was the mean amount
of MSP-133 (in cpm) in control samples incubated in reaction
buffer alone; B was the mean amount of MSP-133 in the 0 h con-
trol (i.e., background levels of MSP-133 present at the start of the
assay); and X was the mean amount of MSP-133 produced in the
presence of the antibody under test or protease inhibitor.
Preparation of Merozoite Antigen Sonicate for Immunoassays.
This study investigated recognition by antibodies of MSP-1 in
the form in which it exists on the surface of the free merozoite.
Since the MSP-1 precursor undergoes proteolytic modification at
or before merozoite release, possibly resulting in conformational
differences between the precursor molecule and the merozoite
surface complex, it was decided to avoid the use of detergent-sol-
ubilized precursor protein for experiments exploring the mecha-
nisms involved in blocking antibody activity, and to use merozo-
ite-derived, nondetergent-solubilized antigen instead. Purified
merozoites were suspended on ice in 0.1 M carbonate/bicarbon-
ate buffer, pH 9.6, 0.02% (wt/vol) sodium azide (coating buffer),
containing the protease inhibitors leupeptin, antipain, TLCK, and
1 mM PMSF. The suspension was sonicated in a Kerry KS 1000
sonicating water bath (Kerry Ultrasonics, Hitchin, Herts., UK)
for 1 min, centrifuged at 12,000 g for 15 min, and then the result-
ing supernatant was further diluted (usually 100-fold) in coating
buffer before being used to coat ELISA or RIA plates.
ELISA. An ELISA was used to titrate the binding of anti-
bodies to native or recombinant MSP-1 and to determine saturat-
ing antibody concentrations under these conditions. Serially di-
luted mAbs, rabbit antibodies, or human antibodies were added
to ELISA plates (Immulon 4; Dynatech Labs., Inc., Chantilly, VA)
coated with an optimal concentration of purified rMSP-119 or
merozoite antigen sonicate. Bound antibody was detected using
horseradish peroxidase-conjugated (HRP) rabbit anti–mouse IgG
or HRP mouse anti–rabbit IgG, or HRP rabbit anti–human IgG
(Sigma Chemical Co., UK) as appropriate. Assays were otherwise
performed and developed as previously described (35). In prelim-
inary experiments, titration curves obtained using anti–MSP-119
mAbs in the two ELISA systems (rMSP-119 and merozoite soni-
cate) were indistinguishable.
Competitive RIA. A competitive solid-phase RIA was used to
determine whether or not anti–MSP-1 mAbs or rabbit antibodies
could competitively block the binding of processing-inhibitory
mAbs 12.8 and 12.10 to their epitopes. Wells of polyvinyl chlo-
ride microtiter plates (Falcon Labware, Becton Dickinson and Co.,
Oxnard, CA) were coated overnight at 48C with 100 ml of mero-
zoite antigen sonicate, or rMSP-119 at a final concentration of 10
mg ml21 in coating buffer. Plates were then washed three times in
PBS/T and treated overnight at 48C with PBS/T containing 1%
(wt/vol) bovine serum albumin (PBS/T/BSA). The plates were
then washed and 50 ml PBS/T/BSA containing serum or purified
antibody at a saturating concentration (predetermined by ELISA;
see above) was added to wells in triplicate. Plates were incubated
for 2 h at room temperature, then washed again, and 50 ml of op-
timally diluted radioiodinated mAb 12.8 or 12.10 was added in
PBS/T/BSA. Optimal concentrations of radiolabeled mAbs were
determined in preliminary radioimmune titration assays; the final
concentration of radiolabeled mAbs used in the competitive RIAs
corresponded to those in the linear part of the dose–response
curve, so that changes in 12.8 and 12.10 binding in the presence
of blocking antibodies would be readily apparent. Plates were in-
cubated for a further 2 h at room temperature, then washed as be-
fore. Individual wells were excised and counted for 1 min in a
gamma counter. Samples were routinely assayed in triplicate, and
the binding of radiolabeled mAbs was expressed as a percentage of
that obtained in the absence of pretreatment of wells.
Affinity Purification of Human Antibodies Reactive with pME6.
Purified pME6 protein was bound to cyanogen bromide–acti-
vated Sepharose 4B (Pharmacia Biotech) at 5 mg ml21 swollen
gel according to the manufacturer’s instructions. 30 ml of pooled
serum derived from adult Gambian donors was diluted 1:4 in 50 mM
Tris-HCl, pH 8.0, containing 0.02% (wt/vol) sodium azide, clar-
ified by passage through a 0.45-mm filter, then passed over a 5-ml
affinity column at a flow rate of 10 ml h21. The column was
washed extensively in 50 mM Tris-HCl, pH 8.0, and bound Ig
was eluted in the same buffer containing 8 M urea. Samples of
eluate fractions were subjected to SDS-PAGE under reducing1692 Blocking Antibodies in Malaria
conditions, and assessed for the presence and purity of IgG by ex-
amination of Coomassie blue–stained gels. Peak fractions were
pooled, dialyzed exhaustively against PBS, concentrated in an ul-
trafiltration cell using an XM10 membrane (Amicon, Inc.), and
stored at 48C. Yield of IgG was quantified by spectrometry as-
suming an A280 for human IgG of 1.4 at 1.0 mg ml21 (1-cm path
length).
Results
Development and Validation of an Assay to Quantitate Anti-
body-mediated Inhibition of MSP-1 Processing. In previous work,
a panel of MSP-119–specific mAbs was tested for their abil-
ity to interfere with secondary processing of MSP-1 (25) us-
ing a Western blot–based procedure that allowed only a
semiquantitative estimate of processing inhibition. To im-
prove the assay for this study, a radioiodinated, affinity-
purified anti–rabbit IgG was used. Autoradiography of the
probed blots allowed visualization of bands corresponding
to MSP-142 and its processed product MSP-133, and the
amount of antibody bound to each was determined by di-
rect counting in a gamma counter. When an extract of in-
cubated merozoites was analyzed by this method, the ra-
dioactivity associated with each of the MSP-133 and MSP-142
bands on the blot was, within limits imposed by the protein
binding capacity of the blotting membrane, directly pro-
portional to the volume of merozoite extract loaded on the
gel (not shown). This linear relationship did not hold if an
extract of more than z2 3 108 merozoites was loaded per
track, and in all subsequent experiments this limit was not
exceeded. During a 1-h incubation of merozoites, the ob-
served decrease over time in the number of counts associ-
ated with MSP-142 (due to processing of the polypeptide)
was concomitant with a corresponding increase in the num-
ber of counts associated with MSP-133, and at least 50% of
the MSP-142 underwent processing in this period (data not
shown; see reference 13). These results are in accordance
with previous data showing stoichiometric conversion of
MSP-142 to MSP-133 (13), and indicated that accurate
quantitation of MSP-1 processing is possible with this assay.
In a typical assay, the number of cpm associated with the
MSP-133 band in the zero time (0 h) control and the posi-
tive processing control sample (incubated for 1 h in reac-
tion buffer only; see Materials and Methods) was 20 and
1,300 cpm, respectively (data not shown).
The assay was used to quantify MSP-1 secondary pro-
cessing and its inhibition by a panel of anti–MSP-119 mAbs.
Washed FCB-1 merozoites were incubated on ice in the
presence of individual purified mAbs, then transferred to
378C for 1 h to allow processing to occur. MSP-142 pro-
cessing in the individual samples was then assessed using the
above protocol. Fig. 1 shows that mAb 12.8, which recog-
nizes a conserved epitope in the first EGF-like motif of
MSP-119 (36, 37), inhibited processing by 96% of the con-
trol value, whereas mAb 12.10, which recognizes an epi-
tope formed by the two EGF-like motifs together (37),
inhibited processing by 98%. Monoclonal antibody 1E1
showed no processing-inhibitory activity in this assay sys-
tem. Interestingly, our earlier data obtained using a semi-
quantitative Western blot–based assay indicated that mAb
1E1 appeared to induce abnormal processing rather than pre-
venting the processing; in addition, mAb 1E1 does not pre-
vent erythrocyte invasion in in vitro cultures of P. falci-
parum (25). Antibodies 8A12 and 117.2 inhibited MSP-142
processing by 18 and 12%, respectively, whereas mAbs 111.4,
12D11, and 7E5 did not detectably prevent processing.
Neither mAb 89.1, which recognizes an epitope within the
NH2-terminal domain of MSP-1 (MSP-183), nor the anti–
P. yoelii MSP-1 mAb 25.1, had any effect on the processing
(data not shown). These results confirm that mAbs 12.8
and 12.10 are potent inhibitors of MSP-142 processing. In
similar assays using merozoites of the P. falciparum clone
T9/96, which expresses the alternative dimorphic form of
MSP-1 (31), but retains the nonpolymorphic epitopes rec-
ognized by mAbs 12.8 and 12.10 (38), both mAbs showed
similarly potent processing inhibition activity (data not
shown).
Blocking Antibodies Act by Competitively Preventing the Binding
of Processing-inhibitory mAbs to Merozoites. Previous work (25)
has indicated that a number of anti–MSP-119 mAbs, which
themselves do not inhibit MSP-1 processing, can block the
ability of mAbs 12.8 and 12.10 to interfere with the pro-
cessing. Although the mechanism of this blocking activity
was not elucidated, the most likely explanation is that a
blocking antibody can compete with a processing-inhibi-
tory antibody for binding to MSP-1 on the merozoite sur-
face. In this study, this hypothesis was directly tested using a
competitive RIA to investigate the effects of known block-
ing antibodies on binding of processing-inhibitory antibodies
to native, merozoite-derived MSP-1.
Wells of 96-well polyvinyl chloride plates coated with
merozoite antigen extract were incubated with anti–MSP-119
Figure 1. Inhibition of MSP-142 processing by anti–MSP119 mAbs.
Washed FCB-1 merozoites were either immediately detergent solubilized
(0h) or incubated for 1 h at 378C in the presence of no antibodies (noAb),
1 mM PMSF as inhibitor control, or purified mAbs 12.10, 12.8, 1E1,
111.4, 8A12, 12D11, 7E5 or 117.2, all at a final concentration of 300 mg
ml21. MSP-1 secondary processing in the samples was then quantified as
described. All samples were tested in triplicate, and percentage of process-
ing was calculated as described in Materials and Methods.1693 Guevara Patiño et al.
mAbs at saturating concentrations. The plates were then
washed and an optimal concentration of radioiodinated mAb
12.8 or 12.10 was added. After further incubation, plates
were washed and individual wells were counted directly in
a gamma counter. Fig. 2 shows that antibodies known to
interfere with the processing activity of mAbs 12.8 and
12.10 prevented these mAbs from binding to immobilized
antigen. Although mAbs 7.5 and 1E1 prevented binding of
both radiolabeled mAbs, mAb 2.2 only significantly pre-
vented binding of mAb 12.8, consistent with its ability to
interfere with the processing-inhibitory activity of mAb
12.8 but not 12.10 (25). Preincubation with mAb 111.4
had little or no effect on binding of the radiolabeled mAbs,
consistent with its lack of blocking activity (25); mAb 89.1
was similarly ineffective in competing with 12.8 or 12.10
binding. Identical results were obtained when rMSP-119 was
used to coat RIA plates (data not shown).
Antibodies Against the NH2-terminal Region of MSP-1 Can
Block the Binding of Processing-inhibitory mAbs Directed against
Epitopes within MSP-119. The above results showed that
the binding of processing-inhibitory antibodies to MSP-119
can be specifically prevented by the interaction of other an-
tibodies with the same polypeptide, and explained how block-
ing antibodies interfere with the processing-inhibitory ac-
tivity of mAbs 12.8 and 12.10. Interestingly, Wilson et al. (38)
found that mAb 13.2, which recognizes an epitope within
the NH2-terminal domain of MSP-1, prevents the binding
of mAb 12.8 to intact MSP-1, raising the possibility that anti-
bodies specific to other components of the MSP-1–derived,
merozoite surface protein complex might have blocking ac-
tivity. To investigate this possibility, a series of rabbit anti-
bodies, raised against recombinant proteins corresponding
to regions covering all of MSP-1 (reference 8; Fig. 3) were
tested for their ability to competitively prevent recognition
of merozoite-derived MSP-1 by mAbs 12.8 and 12.10. Fig.
4 shows that binding of radioiodinated mAbs 12.8 and
12.10 to the merozoite antigen was significantly blocked by
some but not all of the polyclonal antibodies. The fact that
rabbit antibodies raised against pME12, 16, and 20 were
able effectively to block binding was not unexpected, due
to the presence of the 12.8 and 12.10 epitopes within the
sequence of the recombinant proteins used to raise these
rabbit sera. However, it was found that antibodies raised
against constructs corresponding to domains of MSP-1 out-
side the COOH-terminal region also showed potent
blocking activity; in particular, the anti-pME6, anti-
pME14, and anti-pME3 sera inhibited binding of mAb 12.8
to the immobilized antigen by 68, 48, and 91%, respectively,
and the rabbit anti-pME14, anti-pME1, and anti-pME3, but
not the anti-pME6 antibodies, significantly prevented bind-
ing of mAb 12.10. These results show that polyclonal anti-
bodies specific for fragments of the MSP-1 complex other
than MSP-119 can act as blocking antibodies.
Figure 2. The binding of processing-inhibitory mAbs 12.8 and 12.10
to FCB-1 merozoite-derived MSP-1 is competitively prevented by cer-
tain other anti–MSP-1 mAbs. Plates coated with a merozoite antigen ex-
tract were preincubated in triplicate with either no antibody (noAb; con-
trol wells), or with predetermined saturating concentrations of mAbs 12.10,
12.8, 2.2, 111.4, 7.5, 1E1, or 89.1. The effects of this pretreatment on
binding of radioiodinated mAbs 12.8 (A) or 12.10 (B) to the immobilized
antigen was then assessed. All samples were tested in triplicate. Blocking
activity of individual mAbs was calculated as described in Materials and
Methods.
Figure 3. Schematic of recombinant (pME) MSP-1 constructs relative
to the MSP-1 gene and its products. Shown is a diagrammatic representa-
tion of the complete MSP-1 gene, divided into conserved (open) blocks 1,
3, 5, 12, and 17, semiconserved (hatched) blocks 7, 9, 11, 13, and 15, and
poorly conserved or polymorphic (filled) blocks 2, 4, 6, 8, 10, 14, and 16,
as defined by Tanabe et al. (48). The positions of the MSP-1 primary pro-
cessing products (MSP-183, MSP-130, MSP-138 and MSP-142) are shown
relative to the gene, as are the relative positions of the pME series of re-
combinant expression constructs against which polyclonal rabbit antisera
have been raised (8). IgG purified from the anti-pME rabbit sera was used
in this study.1694 Blocking Antibodies in Malaria
Naturally Acquired Human Antibodies Specific for Epitopes
within the NH2-terminal Domain of MSP-1 Block the Activity
of Processing-inhibitory Anti–MSP-119 Antibodies. Antibodies
which prevent MSP-1 processing and erythrocyte invasion
may be involved in mediating protection against blood-stage
parasitemia. If antibodies induced to other domains of
MSP-1 can block the activity of processing-inhibitory anti-
bodies specific for MSP-119, their presence in human sera
may be disadvantageous to the host. In light of the above
data, it was decided to investigate the ability of naturally ac-
quired antibodies, specific for the region of MSP-1 corre-
sponding to pME6, to block the processing-inhibitory ac-
tivity of mAbs 12.8 and 12.10. This particular construct
was chosen because pME6 is readily soluble (8), and the E.
coli clone which expresses pME6 does so at very high lev-
els. Human antibodies reactive with pME6 were isolated
from pooled Gambian adult immune serum by affinity
chromatography on immobilized pME6 fusion protein. The
eluted Ig was judged to be .98% pure as assessed by SDS-
PAGE under reducing conditions (data not shown). The Ig
was concentrated by ultrafiltration and assayed by immuno-
blot for reactivity with FCB-1 merozoite polypeptides.
Strong reactivity was observed with only two merozoite
polypeptides of z83 and 195 kD (Fig. 5); these most likely
correspond to MSP-183 and the residual MSP-1 precursor
protein. Note that the purified antibodies showed no reac-
tivity with the MSP-142 and MSP-119 species (Fig. 5, ar-
rows). In confirmation of this, analysis of the affinity-purified
Ig by indirect immunofluorescence showed strong reactiv-
ity with acetone-fixed FCB-1 or T9/96 schizonts, but none
with newly invaded ring stage parasites, which contain only
MSP-119 (9–12) (data not shown). Note that since the pME6
construct covers much of the highly conserved MSP-1
block 3 domain, as well as all of the conserved block 5 (see
Fig. 3), antibodies against pME6 would be expected to rec-
ognize both allelic forms of MSP-1.
The ability of the affinity-purified human antibodies to
block the processing-inhibitory effects of mAbs 12.8 and
12.10 was then assessed. Merozoites were incubated on ice
in the presence or absence of the human anti-pME6 anti-
bodies, and then mAb 12.8 or 12.10 was added and the
samples were incubated for 20 min on ice before transfer to
378C for 1 h to allow processing to take place. Fig. 6 A shows
that pretreatment with the anti-pME6 antibodies virtually
abolished the processing-inhibitory activity of mAb 12.8, but
interestingly had no effect on the inhibitory activity of mAb
12.10. In parallel binding assays (Fig. 6 B), the anti-pME6
antibodies competed effectively with binding of mAb 12.8,
but not mAb 12.10, to immobilized merozoite-derived an-
tigen.
Figure 4. Rabbit polyclonal antibodies raised against defined domains
of MSP-1 have blocking activity. Rabbit antibodies raised against recom-
binant MSP-1 expression constructs pME1, 3, 5, 6, 7, 8, 11, 12, 13, 14,
16, 17, 18, 19, 20, 22, and 23 were assayed at predetermined saturating
concentrations for their ability to prevent binding of radioiodinated mAb
12.8 or 12.10 to immobilized FCB-1 merozoite antigen. Control wells
were pretreated either with mAbs 12.8 or 12.10, or with buffer alone (No
Ab) or with a nonimmune rabbit serum (NI Rs) at a final dilution of 1:
100. All samples were assayed in triplicate, and SE bars are indicated.
Figure 5. Specificity of affin-
ity-purified human anti-pME6
antibodies shown by Western
blot analysis. An SDS extract of
FCB-1 merozoites was sub-
jected to SDS-PAGE under
nonreducing conditions on a
12.5% gel, transferred to nitro-
cellulose, then probed with a
sample of pooled human im-
mune serum taken before chro-
matography over the pME6 af-
finity column (lane 1); serum
taken after passage over the col-
umn (lane 2); affinity-purified
anti-pME6 antibodies (lane 3);
mAb 89.1 (specific for MSP-183;
lane 4); and mAb 111.4 (specific
for MSP-142 and MSP-119; lane
5). Positions of molecular mass
marker proteins are indicated, and
bands corresponding to the MSP-1
precursor, MSP-183, MSP-142,
and MSP-119 are arrowed.1695 Guevara Patiño et al.
These data clearly show that the binding of antibodies
specific to one component of the MSP-1–derived merozo-
ite surface complex can interfere with the binding of anti-
bodies to another component of the complex. Erythrocyte
invasion by the malaria merozoite is rapid, going to com-
pletion within seconds of the initial interaction between
parasite and red cell surface (39). Over such a short time
span, could the presence of blocking antibodies interfere with
the ability of processing-inhibitory antibodies to bind the
merozoite surface and prevent both processing and inva-
sion? To address this question directly in an in vitro system,
a series of invasion experiments was performed. Mature,
biosynthetically radiolabeled T9/96 schizonts were washed
and placed in culture with fresh red cells. Merozoite release
and red cell invasion were then allowed to proceed in the
presence or absence of mAbs 12.8 and 12.10, with or with-
out the additional presence of affinity-purified anti-pME6
human antibodies. The overall efficiency of invasion was as-
sessed by counting the number of new ring stage parasites
formed over the course of the experiment; MSP-1 process-
ing in individual samples was subsequently assessed by direct
immunoprecipitation of MSP-133 from the culture super-
natants using mAb X509 coupled to Sepharose. In prelimi-
nary dose–response experiments, a concentration of >400
mg ml21 of either mAb 12.10 (Fig. 7 A) or mAb 12.8 (data
not shown) was sufficient to reduce the amount of MSP-133
release to a level of inhibition seen in the presence of 5 mM
EGTA, a potent inhibitor of MSP-1 secondary processing
(11). The results of a typical experiment (of a total of three
independent experiments) investigating the effects of the
anti-pME6 blocking antibodies on the activity of mAbs
12.8 and 12.10 are presented in Fig. 7 B. In isolation, mAbs
12.8 and 12.10 virtually abolished both invasion (Fig. 7 B,
bottom) and MSP-133 release (Fig. 7 B, top). However, in
the presence of equal concentrations of the anti-pME6 hu-
man antibodies, the effects of mAb 12.8, but not of 12.10,
were completely reversed (Fig. 7 B, lanes 5 and 7). Neither
the anti-pME6 antibodies alone nor mAb 89.1 alone had
any effect on either processing or invasion (Fig. 7 B, lanes 3
and 8), and mAb 89.1 exhibited no blocking activity (Fig.
7 B, lanes 9 and 10). These results unambiguously demon-
strate that, under conditions of active release of viable
merozoites, mAbs 12.8 and 12.10 effectively prevent both
MSP-1 processing and erythrocyte invasion, and this activ-
ity can be efficiently abrogated by the presence of human
blocking antibodies.
Discussion
Four major conclusions can be drawn from this study.
First, blocking antibodies function by competitively pre-
venting the binding of processing-inhibitory antibodies to
the merozoite surface, and can be effective under condi-
tions of active merozoite release and erythrocyte invasion.
Second, blocking activity can be mediated not only by an-
tibodies specific for the MSP-119 domain, but also by anti-
bodies binding to polypeptides other than the MSP-119 tar-
get of processing-inhibitory antibodies; here we have shown
that antibodies reactive with a region within MSP-183, a
polypeptide derived from the NH2-terminal domain of the
MSP-1 precursor, possess potent blocking activity. Anti-
bodies against other fragments of the merozoite surface
complex, possibly including the non–MSP-derived com-
ponents of it (12, 40), may also mediate blocking activity;
indeed, our present data suggest that antibodies against the
region of MSP-1 represented by pME14 possess significant
blocking activity (Fig. 4). Third, human blocking antibod-
ies can be induced by natural exposure to malarial infec-
tion. Fourth, if prevention of MSP-1 processing is a major
mechanism by which anti–MSP-119 antibodies exert their
effect on erythrocyte invasion by the P. falciparum merozo-
ite, then the protective potential of inducing such antibod-
ies by vaccination could be impaired by a preexisting or si-
multaneously induced blocking antibody response directed
against MSP-119 itself, or other components of the MSP-1
protein complex.
Figure 6. Affinity-purified, naturally acquired human anti-pME6 anti-
bodies are potent blocking antibodies. (A) Equal aliquots of washed FCB-1
merozoites were solubilized directly into detergent (0 h control), or pre-
incubated either with reaction buffer only or with affinity-purified human
anti-pME6 antibodies at a final concentration of 300 mg ml21. An equal
concentration of mAb 12.10 or 12.8 was then added to some samples as
shown, and processing was allowed to proceed for 1 h in all but the 0 h
control. Inhibition of MSP-1 processing mediated by mAb 12.8 alone (96%)
was almost completely reversed by preincubation with the anti-pME6 an-
tibodies, whereas the inhibition of processing mediated by mAb 12.10
alone (97%) was completely unaffected by preincubation with anti-pME6
antibodies. (B) RIA plates coated with merozoite antigen were pretreated
with nonradioactive mAb 12.10 or 12.8 at a saturating concentration (100 mg
ml21), or affinity-purified anti-pME6 antibodies at a saturating concentra-
tion (300 mg ml21), or nonimmune human serum (NI Hs) at an equiva-
lent final antibody concentration, before assessing the ability of radioiodi-
nated mAb 12.8 or 12.10 to bind. All samples were assayed in triplicate,
and SE bars are shown.1696 Blocking Antibodies in Malaria
MSP-1 is receiving increasing interest as a candidate an-
tigen for a blood-stage malaria vaccine. Experimental pas-
sive immunization and direct immunization-challenge studies
focusing on the protective capacity of anti–MSP-119 anti-
body responses have been substantiated by epidemiological
studies in malaria-endemic areas showing a significant posi-
tive association between levels of serum antibodies against
MSP-119 and resistance to morbidity associated with falci-
parum malaria (41, 42). However, the seroepidemiological
data are ambiguous. For example, there is not a simple rela-
tionship between seropositivity and clinical immunity, and
there is extensive evidence that parasite replication can take
place in vivo in the presence of substantial levels of circu-
lating anti–MSP-1 antibody (41–43). With no clear con-
sensus on either the mechanism(s) by which anti–MSP-1
antibodies control replication of the parasite or the biologi-
cal function of MSP-1 on the merozoite surface (6, 44), the
effector mechanisms required of an optimally protective anti–
MSP-1 immune response have been unclear. Given the
imminent availability of first generation MSP-119-based vac-
cines for clinical evaluation, there is a pressing need to de-
fine indicators of a protective anti–MSP-1 response which
are amenable to quantitative serological assay (45).
We propose that antibodies specific for the P. falciparum
MSP-119 domain prevent merozoites from invading eryth-
rocytes primarily by interfering with MSP-1 secondary
processing. This hypothesis is supported by the apparently
absolute correlation between antibody-mediated processing-
inhibitory activity and invasion inhibitory activity; of a to-
tal of 11 distinct anti–P. falciparum MSP-119 mAbs tested to
date, only mAbs 12.8 and 12.10 exhibit either activity (this
study, reference 25, and our unpublished data). The hy-
pothesis would explain the observed absence of a straight-
forward correlation between total serum anti–MSP-119 an-
tibody levels, and immunity to blood-stage parasitemia in
individuals naturally exposed to malaria; since many anti–
MSP-119 antibody specificities clearly have no effect on
MSP-1 processing, and indeed can block the activity of an-
tibodies with “protective,” processing-inhibitory specificities,
a simple evaluation of total anti–MSP-119 serum antibody
titers in a naturally exposed individual may never provide a
clear measure of the protective capacity of that antibody
response. The additional fact, highlighted in this study, that
blocking activity may also be mediated by naturally ac-
quired antibodies against MSP-1–derived components other
than MSP-119, further complicates attempts to predict the
protective capacity of an antibody response to MSP-119 in
the presence of a polyclonal response against the total MSP-1.
Therefore, the validity of the continued use of simple ELISA-
based assays in epidemiological studies may be question-
able. We tentatively conclude that only a functional assay,
such as one measuring MSP-1 processing inhibition, or the
effect on invasion of affinity-purified antibodies (43), can
provide an assessment of the overall protective capacity of
Figure 7. Processing-inhibitory anti–MSP119
mAbs can prevent MSP-1 and erythrocyte invasion
in in vitro culture, and can be rendered ineffective
by the simultaneous presence of anti-pME6 block-
ing antibodies. (A) Dose–response effect of mAb
12.10 on MSP-1 secondary processing. Metaboli-
cally radiolabeled T9/96 schizonts were supple-
mented with fresh erythrocytes and medium to ob-
tain a parasitemia of z2% and a hematocrit of 1%.
The culture was then divided into equal aliquots
and incubated at 378C in the presence of 5 mM
EGTA as control inhibitor (lane 1), or mAb 12.10
at a final concentration of 2 mg ml21 (lane 2), 1 mg
ml21 (lane 3), 500 mg ml21 (lane 4), 400 mg ml21
(lane 5), 300 mg ml21 (lane 6), 200 mg ml21 (lane
7), 100 mg ml21 (lane 8), or no antibody (lane 9).
Schizont rupture and merozoite release were then
allowed to proceed for 6 h, and culture superna-
tants were analyzed by immunoprecipitation using
mAb X509 coupled to Sepharose for the presence
of MSP-133. (B) Blocking anti-pME6 antibodies re-
verse the processing-inhibitory (top) and invasion-
inhibitory (bottom) activity of mAb 12.8. Cultures
containing metabolically radiolabeled T9/96 schiz-
onts prepared as described above were incubated in
the presence of 5 mM EGTA (lane 1), 10% (vol/
vol) nonimmune human serum (lane 2), anti-pME6
antibodies (lane 3), mAb 12.8 (lane 4), mAb 12.8
plus anti-pME6 antibodies (lane 5), mAb 12.10
(lane 6), mAb 12.10 plus anti-pME6 antibodies
(lane 7), mAb 89.1 (lane 8), mAb 89.1 plus mAb
12.8 (lane 9) and mAb 89.1 plus mAb 12.10 (lane 10). In this case all antibodies were added to a final concentration of 400 mg ml21. Analysis of 6-h cul-
ture supernatants by immunoprecipitation with mAb X509 (B, top) was as above, and in addition erythrocyte invasion in individual cultures was assessed
by counting the number of ring-stage parasites in 5,000 red cells, in triplicate (B, bottom). Invasion is expressed as a percentage of the ring-stage para-
sitemia (10%) obtained in a control culture with no additions (data not shown).1697 Guevara Patiño et al.
an anti–MSP-1 antibody response. The critical test of our
hypothesis will be the predictive power of the assay; oppor-
tunities to evaluate this will arise from immunization trials
in naive primates or humans with MSP-119 or MSP-142–
based vaccines in which significant protection is achieved
(46, 47). This is a major priority, and work towards it is in
progress. A further implication of our hypothesis is that, for
an MSP-119–based vaccine to be effective, its design or mode
of administration should be such that the overall balance of
the induced antibody response is towards processing-inhib-
itory antibody specificities, rather than blocking specifici-
ties. Selectively inducing this type of functional antibody
response may be the major challenge in MSP-119–based
vaccine development.
How do antibodies specific for the NH2-terminal domain
of MSP-1 (MSP-183) exert blocking activity? There are no
published structural data on the merozoite surface complex.
However, treatment of intact merozoites with the bifunc-
tional, cleavable cross-linker 3, 39-dithiobis(sulfosuccinimi-
dylpropionate) results in almost quantitative cross-linking
of the MSP-183 and MSP-142 components of the complex
(Blackman, M.J., unpublished data), suggesting that at least
in the conformation adopted by the membrane-bound form
of the complex, these two polypeptides are spatially close.
Given the additional fact that the molecular mass of an IgG
molecule is not much less than that of the monomeric MSP-1
complex, the observation of steric competition between
anti–MSP-183 and anti–MSP-119 antibodies is perhaps un-
surprising. However, it is not clear why polyclonal anti-
bodies reactive with the part of MSP-183 represented by
pME6 should selectively block binding of mAb 12.8, but
not 12.10; presumably the two processing-inhibitory mAbs
adopt quite distinct orientations on binding. Whatever the
case, this work has provided the first experimental evidence
that antibodies against one part of a merozoite surface pro-
tein can “shield” the parasite from the potentially harmful
effects of antibodies directed against another part of the same
surface protein. MSP-183 is known to be immunogenic in
human populations exposed to malaria (35, 41); it is con-
ceivable that it is advantageous to the parasite to evoke an
antibody response to this part of MSP-1, and this may pro-
vide a selective pressure to prevent sequence variation in
the conserved parts of the molecule.
The physiological function of the proteolytic processing
of MSP-1, and the identity of the protease which mediates
it, are unknown. However, these results reemphasize the
importance of the processing step, and the potential of the
relevant enzyme as a novel target for development of pro-
tease inhibitor–based antimalarial drugs.
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